Education
About Us
Working with TipRanks
Follow Us
Brainsway (BWAY)
:BWAY
BWAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.61 - $11.79
Previous CloseN/A
Volume9.67K
Average Volume (3M)65.07K
Market Cap
$169.10M
Enterprise Value$105.72M
Total Cash (Recent Filing)$4.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)55.9
Beta1.77
Next Earnings
May 07, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding18,869,228
10 Day Avg. Volume28,921
30 Day Avg. Volume65,071
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.29
Price to Cash Flow (P/CF)16.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda26.97
Forecast
1Y Price Target
$16.00Price Target Upside76.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Brainsway News
PremiumCompany Announcements
BrainsWay Reports Strong Growth and Positive Outlook
PremiumCompany Announcements
BrainsWay Reports Strong 2024 Financial Growth
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalBrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, increasing the upper limit of age range from 68 to 86 years of age.
Market ExpansionEast Asian market penetration advances with the placement of 15 new systems in Taiwan and South Korea.
RevenueThe company recorded $11.4M in top-line revenue, beating analyst's forecast of $10.7M.
Bears Say
Market CompetitionThe entry into the Canadian market last year via an exclusive multi-year distribution agreement may face intense competition from established local players.
Research And DevelopmentThe National Institutes of Health granted roughly $1.5 million to explore the efficacy of Brainsway’s Deep TMS system in treating substance use addictions, but results and commercialization timelines remain uncertain.
---
Ownership Overview
―
Insiders
0.53% Mutual Funds
24.31% Other Institutional Investors
74.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BWAY FAQ
What was Brainsway’s price range in the past 12 months?
Brainsway lowest stock price was $4.61 and its highest was $11.79 in the past 12 months.
What is Brainsway’s market cap?
Brainsway’s market cap is $169.10M.
When is Brainsway’s upcoming earnings report date?
Brainsway’s upcoming earnings report date is May 07, 2025 which is in 32 days.
How were Brainsway’s earnings last quarter?
Brainsway released its earnings results on Mar 11, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.022 by $0.018.
Is Brainsway overvalued?
According to Wall Street analysts Brainsway’s price is currently Undervalued.
Does Brainsway pay dividends?
Brainsway does not currently pay dividends.
What is Brainsway’s EPS estimate?
Brainsway’s EPS estimate is 0.02.
How many shares outstanding does Brainsway have?
Brainsway has 18,869,228 shares outstanding.
What happened to Brainsway’s price movement after its last earnings report?
Brainsway reported an EPS of $0.04 in its last earnings report, beating expectations of $0.022. Following the earnings report the stock price went up 4.679%.
Which hedge fund is a major shareholder of Brainsway?
Currently, no hedge funds are holding shares in BWAY
---
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (76.21% Upside)
$16.00 (76.21% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.56%
12-Months-Change
Fundamentals
Return on Equity
5.62%
Trailing 12-Months
Asset Growth
49.25%
Trailing 12-Months
Company Description
Brainsway
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
---
BWAY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, successful expansion of the Deep TMS system, and consistent positive financial performance. While there was an increase in operating expenses, the company's strategic initiatives and future growth prospects remain strong.Read More>---
BWAY Stock 12 Month Forecast
Average Price Target
$16.00
▲(76.21% Upside)
Technical Analysis
Best Analysts Covering BWAY
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+50.63%
assigned a buy rating 11 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +50.63% per trade.
---